Clinical Trial Update: Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing rapamycin to vigabatrin for prevention of Tuberous Sclerosis Complex symptoms in infants, spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberous Sclerosis Complex

Drugs mentioned

• Rapamycin (sirolimus)
• Vigabatrin (Vigabatrin)

Snippet

Sponsor: Katarzyna Kotulska | Conditions: Tuberous Sclerosis Complex | Phase 2, Phase 3 | Status: UNKNOWN